A novel virus is a virus that has never been identified in humans before. It may be entirely new to science, or it may be a known animal virus that has crossed into people for the first time. The critical feature is that the human immune system has no prior experience with it, which means almost nobody carries protective antibodies. That immunological blank slate is what separates a novel virus from the seasonal bugs that circulate year after year.
What Makes a Virus “Novel”
More than 200 viruses are known to cause disease in humans, and new ones continue to be discovered. A virus earns the label “novel” when it appears in a human population that has little or no herd immunity against it. This can happen in two main ways: a completely unknown virus surfaces for the first time, or a familiar virus changes so dramatically that the immune system treats it as something brand new.
The 2009 H1N1 influenza strain is a clear example. The H1N1 subtype had circulated before, but the version that emerged in the spring of 2009 contained a unique combination of genes never previously identified in animals or people. Because human immune systems didn’t recognize it, it spread globally within weeks and was designated a pandemic strain. Similarly, SARS-CoV (2003), MERS-CoV (2012), and SARS-CoV-2 (2019) were all coronaviruses that had not been seen in humans before they spilled over from animal hosts.
How Novel Viruses Emerge
Most novel viruses originate in animals. The jump from an animal species to humans is called zoonotic spillover, and it can happen through several routes. Direct transmission occurs when a person is bitten by or handles an infected animal, or comes into contact with its blood or secretions. Indirect transmission can involve an intermediate host: a domestic animal picks up the virus from wildlife and then passes it to a person, or a mosquito carries it between species. Contaminated environments play a role too, as when an infected animal sheds virus in its feces and a person later encounters it.
MERS-CoV illustrates the intermediate-host pathway well. Bats are believed to be the original reservoir, but dromedary camels became an established host, and human cases in the Arabian Peninsula beginning in 2012 were linked to close contact with camels. SARS-CoV-2 followed a similar pattern of moving from a wildlife reservoir into people, though the precise intermediate host (if any) remains debated.
Reassortment: Mixing and Matching Genes
Influenza viruses have a particular trick that accelerates the creation of novel strains. Their genetic material is split into eight separate segments. When two different flu viruses infect the same cell at the same time, those segments can get shuffled during replication, producing a hybrid virus with a new genetic combination. This process, called reassortment, is how the 2009 pandemic H1N1 strain was born. Reassortment of H3N2 strains with both pandemic and pre-pandemic H1N1 strains has also produced H1N2 viruses that circulated in humans.
Research published in PLOS Pathogens found that how readily two flu strains swap genes depends on the specific strains involved, not just on whether they belong to different subtypes. Some strain pairings reassort frequently; others rarely do. This means predicting which combinations will generate the next novel strain is harder than simply watching for encounters between different subtypes.
Why No Immunity Matters So Much
When a seasonal virus circulates, most adults have some degree of protection from past infections or vaccinations. Their immune cells recognize the virus quickly and mount a response before it can do serious damage. A novel virus sidesteps all of that. With no pre-existing antibodies in the population, the virus can infect nearly anyone it reaches, and severe illness tends to be more common because the immune system is starting from scratch.
This principle was reinforced during the COVID-19 pandemic and, on a smaller scale, during the post-lockdown resurgence of common childhood infections. After prolonged periods of reduced exposure to everyday pathogens, the pool of people with no immunity to those viruses expanded significantly. Infants born during that window received fewer protective antibodies from their mothers, and adults lost some of their own immunity through lack of re-exposure. The result was a sharp rise in hospitalizations for infections like RSV (respiratory syncytial virus) once social mixing resumed. A truly novel virus creates this same dynamic on an even larger scale, because nobody, regardless of age, has encountered it before.
How Scientists Detect an Unknown Virus
Identifying something you’ve never seen before is a challenge. The process typically starts when clinicians notice a cluster of patients with a distinctive illness that doesn’t match any known pathogen. Standard lab tests come back negative, raising suspicion that something new is circulating.
The key technology is a technique called metagenomic sequencing. Instead of testing for one virus at a time, it reads all the genetic material present in a blood or tissue sample at once. Software then pieces those fragments together and compares them against databases of known organisms. If the assembled sequence doesn’t match anything on file, or matches only distantly related animal viruses, researchers may be looking at a novel pathogen. This approach was used to identify a previously unknown virus called HCirV-1, which was found at high levels in the blood and liver tissue of an immunocompromised patient. Standard lab methods had missed it entirely.
The limitation is that the technique works best when at least some related viral sequences already exist in reference databases. Detecting a virus from a completely uncharacterized family is possible but harder, because the software needs some frame of reference to flag a sequence as viral rather than background noise.
Preparing for Viruses That Don’t Exist Yet
Public health agencies don’t wait for a novel virus to appear before they start planning. The World Health Organization maintains a priority pathogen list that includes a placeholder called “Disease X,” representing the possibility that the next pandemic could come from an organism not yet known to cause human disease. The list is evaluated using scientific criteria, public health impact, and socioeconomic factors.
On the vaccine side, the National Institute of Allergy and Infectious Diseases (NIAID) has adopted a “prototype pathogen” strategy. Rather than trying to develop a vaccine for every individual virus, researchers study representative viruses within each major viral family. They map how those viruses enter cells, which animal models best mimic human disease, and which vaccine designs are most promising. The idea is that when a novel virus emerges from that family, much of the groundwork is already done and can be adapted quickly. This is essentially what happened with COVID-19 vaccines: years of prior research on related coronaviruses allowed vaccine development to move at unprecedented speed.
Seasonal surveillance fills in the rest of the picture. The CDC models hospitalization scenarios each year based on the possible emergence of new variants with different levels of immune escape. For the 2025-2026 respiratory season, for instance, the agency projected that a variant with moderate immune-escape properties could drive peak weekly COVID-19 hospitalization rates to 6.7 to 9.5 per 100,000 people. These models give hospitals and public health officials a concrete range to plan around, updated every two months as new data arrive.
Novel Virus vs. New Variant
It’s worth distinguishing between a truly novel virus and a new variant of an existing one. A variant, like the Omicron lineage of SARS-CoV-2, is a mutated version of a virus your immune system has likely encountered before. It may partially dodge your antibodies, causing a new wave of infections, but most people still have some residual protection. A novel virus offers no such safety net. The entire population is immunologically naive, transmission can be explosive, and the severity of disease is unpredictable until enough cases accumulate to paint a clear picture.
That unpredictability is the core reason novel viruses command so much attention from public health systems. Many clinical syndromes that doctors see daily, from unexplained pneumonia to encephalitis to hepatitis, have no identifiable infectious cause. Some of those cases may eventually be traced to viruses that haven’t been discovered yet. The tools to find them are improving rapidly, but the gap between what exists in nature and what science has cataloged remains vast.